# Lipella Pharmaceuticals Inc. (LIPO) Source: https://www.quantisnow.com/company/LIPO Generated: 2026-11-11T12:31:05.955Z - Ticker: LIPO - Exchange: NASDAQ - Sector: Health Care - Industry: Biotechnology: Pharmaceutical Preparations - IPO year: 2022 - SEC CIK: 0001347242 ## Latest LIPO news and filings - 2026-07-15 14:38 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6637980) - 2026-03-31 00:23 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-bankruptcy-or-receivership-6477559) - 2026-02-04 21:19 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-6375386) - 2025-11-14 21:46 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-lipella-pharmaceuticals-inc-6281184) - 2025-10-21 20:18 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-6240218) - 2025-10-09 21:00 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-6229218) - 2025-09-18 12:01 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6205042) - 2025-09-18 12:00 UTC [Public Offering] [Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus](https://www.quantisnow.com/insight/lipella-pharmaceuticals-announces-positive-final-results-from-phase-2a-study-6204996) - 2025-09-15 12:00 UTC [Public Offering] [Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus](https://www.quantisnow.com/insight/lipella-pharmaceuticals-to-present-at-zacks-scr-life-sciences-virtual-6200344) - 2025-08-14 21:07 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-lipella-pharmaceuticals-inc-6167017) - 2025-06-25 19:14 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6098787) - 2025-06-25 19:15 UTC [Public Offering] [Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting](https://www.quantisnow.com/insight/lipella-pharmaceuticals-issues-letter-from-the-ceo-to-stockholders-following-6098786) - 2025-06-20 20:02 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-6093620) - 2025-06-20 19:19 UTC [Public Offering] [Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market](https://www.quantisnow.com/insight/lipella-pharmaceuticals-announces-delisting-from-nasdaq-capital-market-6093561) - 2025-06-17 12:30 UTC [Public Offering] [Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology](https://www.quantisnow.com/insight/lipella-pharmaceuticals-announces-us-patent-issuance-for-diagnostic-technology-6089317) - 2025-06-16 20:25 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-other-events-6088122) - 2025-06-10 20:30 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Lipella Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-lipella-pharmaceuticals-inc-6080636) - 2025-06-04 12:30 UTC [Public Offering] [Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development](https://www.quantisnow.com/insight/lipella-pharmaceuticals-re-signs-manufacturing-collaboration-agreement-with-cook-myosite-to-6071678) - 2025-05-16 20:05 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-6045150) - 2025-05-15 13:10 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6041130) - 2025-05-15 13:00 UTC [Public Offering] [Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting](https://www.quantisnow.com/insight/lipella-pharmaceuticals-to-present-phase-2a-data-for-lp-310-in-6041048) - 2025-05-14 21:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-lipella-pharmaceuticals-inc-6039827) - 2025-04-23 12:30 UTC [Public Offering] [Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"](https://www.quantisnow.com/insight/lipella-pharmaceuticals-abstract-on-oral-lichen-planus-treatment-accepted-for-5997504) - 2025-04-22 09:30 UTC [Public Offering] [Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025](https://www.quantisnow.com/insight/lipella-reports-positive-phase-2a-results-from-second-lp-310-cohort-5995301) - 2025-04-14 10:08 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-other-events-5986064) - 2025-04-09 21:06 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-material-modification-to-5983136) - 2025-04-08 09:00 UTC [Public Offering] [Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus](https://www.quantisnow.com/insight/lipella-pharmaceuticals-completes-enrollment-in-phase-2a-trial-of-lp-310-5980360) - 2025-04-07 23:16 UTC [SEC Form 4] [SEC Form 4 filed by Officer Kaufman Jonathan H](https://www.quantisnow.com/insight/sec-form-4-filed-by-officer-kaufman-jonathan-h-5980261) - 2025-04-07 10:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Lipella Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-lipella-pharmaceuticals-inc-5978780) - 2025-04-04 21:14 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Lipella Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-lipella-pharmaceuticals-inc-5978406) - 2025-04-04 20:06 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Lipella Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-lipella-pharmaceuticals-inc-5977864) - 2025-04-04 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Lipella Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-lipella-pharmaceuticals-inc-5977146) - 2025-03-31 22:52 UTC [SEC Form D] [SEC Form D filed by Lipella Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-lipella-pharmaceuticals-inc-5968180) - 2025-03-31 15:00 UTC [Public Offering] [Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast](https://www.quantisnow.com/insight/lipella-pharmaceuticals-co-founder-michael-chancellor-featured-on-the-pharmaverse-podcast-5966583) - 2025-03-28 10:21 UTC [SEC Form S-3] [SEC Form S-3 filed by Lipella Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-lipella-pharmaceuticals-inc-5964026) - 2025-03-27 23:56 UTC [SEC Form 10-K] [SEC Form 10-K filed by Lipella Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-lipella-pharmaceuticals-inc-5963974) - 2025-03-18 21:01 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-5950360) - 2025-03-18 00:12 UTC [SEC Form 4] [SEC Form 4 filed by Officer Kaufman Jonathan H](https://www.quantisnow.com/insight/sec-form-4-filed-by-officer-kaufman-jonathan-h-5948277) - 2025-03-12 00:01 UTC [SEC Form 4] [SEC Form 4 filed by Officer Kaufman Jonathan H](https://www.quantisnow.com/insight/sec-form-4-filed-by-officer-kaufman-jonathan-h-5939507) - 2025-03-11 21:26 UTC [SEC Form 8-K] [Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lipella-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-5939055) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/LIPO - Earnings history: https://www.quantisnow.com/earnings/LIPO - Dividend history: https://www.quantisnow.com/dividends/LIPO - Insider transactions: https://www.quantisnow.com/insiders/LIPO - Options chain: https://www.quantisnow.com/options/LIPO - SEC 8-K filings only: https://www.quantisnow.com/company/LIPO/8-k - RSS and alerts for LIPO: https://www.quantisnow.com/docs/rss-feeds.md